Amicus Therapeutics Inc
0.0 %
-22.0 %
Yet to be announced
Company Overview
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering novel medicines for rare metabolic diseases. The company's lead product, Galafold® (migalastat), is an oral precision medicine for the treatment of Fabry disease. They also have AT-GAA, a novel treatment paradigm for Pompe disease in late-stage development.
Revenue Sources
Based on review of SEC filings and company reports, Amicus Therapeutics generates revenue primarily from the sale of Galafold®, its FDA-approved treatment for Fabry disease. The company's revenue streams come from legitimate pharmaceutical sales and do not include any haram sources. There are no indications of gambling, alcohol, tobacco, or other prohibited revenue sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $141.52m | $132.55m | - | $12.69m | 0.00% | 9.58% |
| June 30, 2024 | $126.67m | $124.21m | - | $12.51m | 0.00% | 10.07% |
| March 31, 2024 | $110.4m | $150.56m | - | $12.44m | 0.00% | 8.26% |
| Dec. 31, 2023 | $115.08m | $145.78m | - | $26.76m | 0.00% | 18.36% |
The company is in its commercial stage with established revenue from Galafold® sales. Analyzing the last four quarters: Interest expense ranges from 8.3% to 18.4% of total expenses. The company's high interest expense ratios relative to total expenses is concerning from a Shariah compliance perspective.
Operational Ethics
After reviewing company disclosures and operations, there is no evidence of significant ongoing associations with Israel, the Chinese Communist Party, or other entities involved in human rights violations. The company's main operations are in the United States and Europe.
Login to join the discussion